分散式临床试验市场－全球产业规模、份额、趋势、机会及预测（依研究设计、治疗领域、最终用户、地区及竞争格局划分，2021-2031年）

全球分散式临床试验 (DCT) 市场预计将从 2025 年的 104.6 亿美元大幅成长至 2031 年的 232.4 亿美元，复合年增长率达 14.23%。

分散式临床试验是一种研究执行模式，在这种模式下，研究活动透过远端方式进行，利用远距远端医疗、行动医疗服务和数数位资料收集工具，有效降低了对实体研究中心的依赖。这个市场的主要驱动力在于：克服地域限制以增加患者多样性；透过提高便利性来提升参与者的留存率；以及为支持这种以患者为中心的研究方法，对持续收集真实世界数据的需求日益增长。

然而，儘管这些优势显而易见，但市场扩张的一大障碍是研究中心面临的营运复杂性和管理负担。数位平台固有的片段化常常迫使研究中心工作人员在多个互不相连的系统间切换，导致工作流程效率低下，并增加了训练需求。根据临床研究专业人员协会 (ACRP) 预测，到 2024 年，38% 的临床研究中心将把日益复杂的临床试验列为一项主要的营运挑战，这凸显了将这些远端技术整合到标准作业流程中的巨大困难。

市场驱动因素

患者族群多样化和招募效率的提高是全球分散式临床试验 (DCT) 市场的主要驱动因素。透过利用远端监测和本地医疗服务提供者，DCT 消除了以往将某些人群排除在外的地理障碍，使申办方能够接触到更广泛、更具代表性的目标人群。近期行业数据也支持了这一转变，这些数据表明分散式方法在覆盖代表性不足的群体方面卓有成效。例如，塔夫茨药物研发研究中心 (Tufts Center for the Study of Drug Development) 于 2025 年 1 月发布的分析报告《分散化对临床试验绩效的影响》发现，分散式试验中亚洲受试者的比例达到了 20.9%，较传统中心式试验的 14.2% 有了显着提高。

同时，以患者为中心的试验模式日益普及，正在创造一个以参与者便利性和参与度为优先的市场格局。随着试验通讯协定的要求越来越高，相关人员正在利用数位化工具来减轻病患负担，并确保他们能够持续参与整个试验过程。根据Greenphire于2024年10月发布的《2024年市场洞察调查》，97%的临床研究机构强调，对参与者而言，使用者友善的技术是试验成功的关键因素。随着整个行业营运瓶颈的日益增多，这种对用户友善性和效率的追求至关重要。 WCG Clinical的《2024年报告》显示，35%的研究机构认为研究启动准备是他们面临的最大营运挑战，这凸显了提高效率和以患者为中心的执行策略的迫切需求。

市场挑战

营运复杂性和研究中心面临的行政负担是限制全球分散式临床试验 (DCT) 市场成长的重要瓶颈。儘管分散式模式旨在减轻患者的负担，但实际上，它往往将物流负担转移到研究中心工作人员身上，他们必须应对分散的技术环境。每个研究都需要管理多个独立的登入帐号、培训模组和资料接口，这造成了严重的工作流程效率低下。当研究中心负责人被迫花费更多时间处理非临床行政任务时，其启动和维护新研究的能力就会下降，这直接导致分散式试验的成功率降低。

这种对设施资源的压力对支撑市场成长的研究基础设施的财务和营运永续性产生了严重影响。当设施无法收回与这些效率低下相关的成本时，它们往往不愿意采用分散式通讯协定。根据临床研究机构协会 (SCRS) 预测，到 2024 年，50% 的临床研究机构将面临营运资金少于三个月的情况。这种财务脆弱性部分源自于管理复杂远端技术所带来的无偿资源消耗，迫使许多机构放弃分散式试验，从而限制了市场的扩充性和整体覆盖范围。

市场趋势

由于对高度精确和客观的生理终点指标的需求日益增长，透过医用级可穿戴设备进行连续远端监测正迅速从辅助性新技术发展成为研究通讯协定的核心组成部分。这一趋势标誌着研究方法从间歇性资料收集到持续性资料收集的重要转变，使申办者能够获取纵向健康指标，例如生命体征和睡眠模式，而无需受试者频繁往返诊所。使用者的高度参与日益证明了该技术的实用性，并缓解了人们对远端环境通讯协定依从性的担忧。根据临床研究专业人员协会 (ACRP) 于 2024 年 10 月发表的报导《利用穿戴式数位健康科技增强临床试验》，多项使用穿戴式装置的研究表明，病患依从率高达 70% 至 80%，证实了其在支持严谨的分散式调查方法的有效性。

同时，人工智慧 (AI) 在预测性患者招募方面的应用，正从根本上改变着申办者识别和招募合格研究人群的方式。透过应用先进的机器学习演算法，相关人员可以分析大量资料集，精准识别合适的候选人，从而降低传统入组策略中普遍存在的高失败率。随着企业寻求优化资源配置并加快研究进程，这项技术的应用正从实验性试点走向广泛应用。根据皮斯托亚联盟 (Pistoia Alliance) 于 2024 年 9 月开展的“2024 年未来实验室全球调查”，目前 68% 的生命科学专业人士在其工作​​中运用人工智慧和机器学习技术，上年度的54% 显着增长。这项结果凸显了这些工具在研究工作流程中的快速普及。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球分散式临床试验（DCT）市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依研究设计（介入试验、观察性研究、扩大使用试验）
  • 依治疗领域（肿瘤学、心血管疾病、感染疾病、代谢性疾病、神经病学、免疫学、呼吸系统疾病、其他）
  • 按最终用户（製药/生物技术公司、合约研究组织 (CRO)、学术/研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美分散式临床试验（DCT）市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲分散式临床试验 (DCT) 市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区分散式临床试验（DCT）市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲分散式临床试验 (DCT) 市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲分散式临床试验（DCT）市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球分散式临床试验（DCT）市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• IQVIA Inc.
• Thermo Fisher Scientific Inc.
• Laboratory Corporation of America Holdings
• ICON plc
• Clario
• Science 37, Inc.
• Parexel International Corporation
• Obvio Health USA, Inc.
• Signant Health
• Reify Health, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Decentralized Clinical Trials (DCTs) Market is projected to experience substantial growth, rising from a valuation of USD 10.46 Billion in 2025 to USD 23.24 Billion by 2031, reflecting a CAGR of 14.23%. Decentralized Clinical Trials represent a research execution model that leverages telemedicine, mobile healthcare services, and digital data acquisition tools to conduct study activities remotely, effectively reducing the dependence on physical investigative sites. The market is primarily driven by the necessity to enhance patient diversity by overcoming geographic limitations and the need to improve participant retention through increased convenience, alongside a growing demand for continuous, real-world data collection that supports these patient-focused methodologies.

However, despite these evident benefits, a major obstacle hindering market expansion is the operational complexity and administrative strain placed on investigative sites. The fragmentation inherent in digital platforms frequently compels site staff to navigate multiple unconnected systems, resulting in workflow inefficiencies and heightened training demands. According to the Association of Clinical Research Professionals, in 2024, 38% of clinical research sites cited the increasing complexity of clinical trials as their primary operational challenge, underscoring the significant difficulties associated with integrating these remote technologies into standard practice.

Market Driver

The imperative to improve patient diversity and recruitment efficiency serves as a primary catalyst for the Global Decentralized Clinical Trials (DCTs) Market. By utilizing remote monitoring and local healthcare providers, DCTs dismantle the geographic barriers that have historically excluded specific demographics, enabling sponsors to access a wider and more representative population. This shift is substantiated by recent industry data showing the effectiveness of decentralized methods in reaching underrepresented groups; for instance, the Tufts Center for the Study of Drug Development's January 2025 analysis, 'Impact of Decentralization on Clinical Trial Performance,' revealed that decentralized trials achieved an Asian participant representation of 20.9%, a marked improvement over the 14.2% seen in traditional site-based studies.

Concurrently, the increasing adoption of patient-centric trial models is transforming the market landscape by prioritizing participant convenience and retention. As protocols become more demanding, stakeholders are employing digital tools to alleviate the burden on patients, thereby ensuring sustained engagement throughout the study. According to Greenphire's '2024 Market Trends Survey' from October 2024, 97% of clinical research sites emphasized the importance of ease-of-use technology for participants as a critical factor for trial success. This push for user-friendly efficiency is vital given the broader operational bottlenecks in the industry; WCG Clinical reported in 2024 that 35% of research sites identified study start-up as their top operational challenge, highlighting the urgent demand for streamlined, patient-first execution strategies.

Market Challenge

The operational complexity and administrative burden placed on investigative sites constitute a critical bottleneck restricting the growth of the Global Decentralized Clinical Trials (DCTs) Market. While the decentralized model is designed to alleviate patient burden, it often transfers the logistical weight to site staff who must navigate a fragmented landscape of disparate technologies. The requirement to manage multiple unique logins, training modules, and data interfaces for each study creates significant workflow inefficiencies. As site personnel are compelled to divert increasing amounts of time toward non-clinical administrative tasks, their operational capacity to initiate and maintain new trials diminishes, directly reducing the volume of decentralized studies that can be successfully executed.

This strain on site resources severely impacts the financial and operational sustainability of the research infrastructure necessary to support market growth. When sites are unable to recover the costs associated with these inefficiencies, they become reluctant to adopt decentralized protocols. According to the Society for Clinical Research Sites, in 2024, 50% of clinical research sites reported having three months or less of operating capital. This financial fragility, driven in part by the uncompensated resource drain of managing complex remote technologies, forces many sites to decline participation in decentralized trials, thereby limiting the market's scalability and overall reach.

Market Trends

The integration of Medical-Grade Wearables for Continuous Remote Monitoring is rapidly evolving from a supplementary novelty to a central component of study protocols, driven by the need for high-fidelity, objective physiological endpoints. This trend signifies a critical shift away from episodic data collection, allowing sponsors to capture longitudinal health metrics such as vital signs and sleep patterns without burdening participants with frequent on-site visits. The operational viability of this technology is increasingly validated by strong user engagement, which mitigates concerns regarding protocol compliance in a remote setting; according to the Association of Clinical Research Professionals' October 2024 article, 'Enhancing Clinical Trials with Wearable Digital Health Technologies,' multiple studies utilizing wearable devices demonstrated high patient adherence rates between 70% and 80%, confirming their effectiveness in supporting rigorous decentralized methodologies.

Simultaneously, the adoption of Artificial Intelligence for Predictive Patient Recruitment is fundamentally altering how sponsors identify and engage eligible study populations. By deploying advanced machine learning algorithms, stakeholders can now analyze vast datasets to precisely target suitable candidates, thereby reducing the high failure rates associated with traditional enrollment strategies. This technological integration has transitioned from experimental pilots to widespread operational usage as companies seek to optimize resource allocation and accelerate trial timelines. According to the Pistoia Alliance's September 2024 'Lab of the Future 2024 Global Survey,' 68% of life science professionals reported currently using Artificial Intelligence and Machine Learning in their work, a significant increase from 54% in the previous year that highlights the rapid entrenchment of these tools in research workflows.

Key Market Players

• IQVIA Inc.
• Thermo Fisher Scientific Inc.
• Laboratory Corporation of America Holdings
• ICON plc
• Clario
• Science 37, Inc.
• Parexel International Corporation
• Obvio Health USA, Inc.
• Signant Health
• Reify Health, Inc.

Report Scope

In this report, the Global Decentralized Clinical Trials (DCTs) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Decentralized Clinical Trials (DCTs) Market, By Study Design

• Interventional Trials
• Observational Studies
• Expanded Access Trials

Decentralized Clinical Trials (DCTs) Market, By Therapeutic Area

• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Metabolic Disorders
• Neurology
• Immunology
• Respiratory Diseases
• Others

Decentralized Clinical Trials (DCTs) Market, By End User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutions
• Others

Decentralized Clinical Trials (DCTs) Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Decentralized Clinical Trials (DCTs) Market.

Available Customizations:

Global Decentralized Clinical Trials (DCTs) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Decentralized Clinical Trials (DCTs) Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Study Design (Interventional Trials, Observational Studies, Expanded Access Trials)
  • 5.2.2. By Therapeutic Area (Oncology, Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders, Neurology, Immunology, Respiratory Diseases, Others)
  • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutions, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Decentralized Clinical Trials (DCTs) Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Study Design
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Decentralized Clinical Trials (DCTs) Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Study Design
      • 6.3.1.2.2. By Therapeutic Area
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Decentralized Clinical Trials (DCTs) Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Study Design
      • 6.3.2.2.2. By Therapeutic Area
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Decentralized Clinical Trials (DCTs) Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Study Design
      • 6.3.3.2.2. By Therapeutic Area
      • 6.3.3.2.3. By End User

7. Europe Decentralized Clinical Trials (DCTs) Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Study Design
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Decentralized Clinical Trials (DCTs) Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Study Design
      • 7.3.1.2.2. By Therapeutic Area
      • 7.3.1.2.3. By End User
  • 7.3.2. France Decentralized Clinical Trials (DCTs) Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Study Design
      • 7.3.2.2.2. By Therapeutic Area
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Decentralized Clinical Trials (DCTs) Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Study Design
      • 7.3.3.2.2. By Therapeutic Area
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Decentralized Clinical Trials (DCTs) Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Study Design
      • 7.3.4.2.2. By Therapeutic Area
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Decentralized Clinical Trials (DCTs) Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Study Design
      • 7.3.5.2.2. By Therapeutic Area
      • 7.3.5.2.3. By End User

8. Asia Pacific Decentralized Clinical Trials (DCTs) Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Study Design
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Decentralized Clinical Trials (DCTs) Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Study Design
      • 8.3.1.2.2. By Therapeutic Area
      • 8.3.1.2.3. By End User
  • 8.3.2. India Decentralized Clinical Trials (DCTs) Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Study Design
      • 8.3.2.2.2. By Therapeutic Area
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Decentralized Clinical Trials (DCTs) Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Study Design
      • 8.3.3.2.2. By Therapeutic Area
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Decentralized Clinical Trials (DCTs) Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Study Design
      • 8.3.4.2.2. By Therapeutic Area
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Decentralized Clinical Trials (DCTs) Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Study Design
      • 8.3.5.2.2. By Therapeutic Area
      • 8.3.5.2.3. By End User

9. Middle East & Africa Decentralized Clinical Trials (DCTs) Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Study Design
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Decentralized Clinical Trials (DCTs) Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Study Design
      • 9.3.1.2.2. By Therapeutic Area
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Decentralized Clinical Trials (DCTs) Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Study Design
      • 9.3.2.2.2. By Therapeutic Area
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Decentralized Clinical Trials (DCTs) Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Study Design
      • 9.3.3.2.2. By Therapeutic Area
      • 9.3.3.2.3. By End User

10. South America Decentralized Clinical Trials (DCTs) Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Study Design
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Decentralized Clinical Trials (DCTs) Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Study Design
      • 10.3.1.2.2. By Therapeutic Area
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Decentralized Clinical Trials (DCTs) Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Study Design
      • 10.3.2.2.2. By Therapeutic Area
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Decentralized Clinical Trials (DCTs) Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Study Design
      • 10.3.3.2.2. By Therapeutic Area
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Decentralized Clinical Trials (DCTs) Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. IQVIA Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc.
• 15.3. Laboratory Corporation of America Holdings
• 15.4. ICON plc
• 15.5. Clario
• 15.6. Science 37, Inc.
• 15.7. Parexel International Corporation
• 15.8. Obvio Health USA, Inc.
• 15.9. Signant Health
• 15.10. Reify Health, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer